Cedilla Therapeutics, a company focused on broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation, revealed on Tuesday that it has appointed Delphine Collin PhD as vice president, biomolecular sciences, to advance the company's work to develop and leverage the biophysical and biochemical understanding of ligand-induced stabilisation and degradation of therapeutically relevant protein targets.
Most recently Collin served as chief innovation officer of contract research organisation HarkerBIO. Before that, she was senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimisation in the small molecule drug discovery group.
Collin also started her own consulting firm, Delphine Collin Consulting LLC, while at BI, supporting companies with specialised biophysical approaches to drug discovery.
Earlier in her career, Collin was a research fellow at Merck & Co.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer